HIV infection and AIDS: new biology, therapeutic advances, and clinical implications. Introduction.
Recent advances in our understanding of the pathogenesis of human immunodeficiency virus (HIV) disease and the important role that viral load plays in the initial selection of antiretroviral therapy significantly alters our management of this disease. Guidelines from the British HIV Association, International AIDS Society-USA, and United States Public Health Service panels regarding the selection of appropriate antiretroviral therapy, and from the Centers for Disease Control and Prevention on prophylaxis for opportunistic infections, have recently been published. Despite tremendous advances in treating the disease and its related complications, a comprehensive, long-term disease management plan that includes recognition of patient concerns about quality of life is lacking. New approaches to managing HIV disease must now include strategies that address patient concerns about fatigue, gastrointestinal distress, malnutrition, and weight loss. Patients must become more involved in decisions about selection of specific drugs and drug regimens and must be consulted about their expectations and needs. We have made significant strides in the treatment of HIV disease. We can readily reduce the viral burden to virtually undetectable levels, and we must continue to develop even more potent and tolerable treatment regimens. We can make patients live longer. Helping patients live better quality lives deserves further study.
Miles
S A
SA
University of California, Los Angeles, Center for Clinical AIDS Research and Education, 90095-1793, USA.
D017088:AIDS-Related Opportunistic Infections / Q000523:psychology; D000163:Acquired Immunodeficiency Syndrome / Q000523:psychology / Q000628:therapy* / Q000821:virology*; D015658:HIV Infections / Q000523:psychology / Q000628:therapy* / Q000821:virology*; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D011788:Quality of Life; D019562:Viral Load